Cited by 13Virus-based gene therapy researchRNA Interference and Gene DeliveryRetinal Development and Disorders

A Fragmented Adeno-Associated Viral Dual Vector Strategy for Treatment of Diseases Caused by Mutations in Large Genes Leads to Expression of Hybrid Transcripts

Open access
McClements, Michelle E, Charbel Issa, Peter, Blouin, Veronique, MacLaren, Robert E·2016·Journal of Genetic Syndromes & Gene Therapy

Abstract

Objective: Dual vector AAV systems are being utilised to enable gene therapy for disorders in which the disease gene is too large to fit into a single capsid.Fragmented adeno-associated viral (fAAV) vectors containing single inverted terminal repeat truncated transgenes have been considered as one such gene replacement strategy.Here we aim to add to the current understanding of the molecular mechanisms employed by fAAV dual vector systems.Methods: Oversized (>8 kb) transgene constructs containing ABCA4 coding sequence were packaged as truncated fragments <5 kb in size into various AAV serotypes.In vitro transductions with these fAAV vector preparations were conducted with mRNA and protein expression products assessed by way of RT-PCR, qPCR and western blot techniques.Results: Transductions with fAAV vector preparations yielded ABCA4 mRNA, but did not generate detectable levels of protein.Sequencing of the transcript population revealed the presence of full length ABCA4 CDS with additional hybrid ABCA4 variants, indicating truncated transgenes without regions of overlap were joining and forming stable hybrid transgenes.In contrast, an ABCA4 overlapping dual vector system (OV) with a defined complementary region generated only full length mRNA transcripts plus detectable ABCA4 protein.Conclusion: Despite previous success shown with the fAAV approach, the lack of repeatability and identification of stable hybrid transcripts capable of protein production suggests there is more refinement required before considering this approach in a clinical setting.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4172/2157-7412.1000311

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Low transduction efficiencies and aberrant production of truncated proteins from single AAV vectors have been two major limitations.

    “the low transduction efficiencies as well as the aberrant production of truncated proteins from single AAV vectors have been two major limitations [103,104]”

    From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [104]

    The Discussion (page unavailable) describes the fragmented dual-vector approach as less efficient than other dual-vector methods and predicts that its hybrid transcripts could produce truncated proteins if translated. It does not establish low transduction efficiency for single AAV vectors or demonstrate aberrant production of truncated proteins; the Introduction says translation was not detectable by western blot. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 15 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
McClements, M. E., Charbel Issa, P., Blouin, V., & MacLaren, R. E.
Affiliations
  • University of Oxford (GB)
  • John Radcliffe Hospital (GB)
Venue
Journal of Genetic Syndromes & Gene Therapy
Published
2016
Volume
7
Issue
5
Pages
311
ISSN
2157-7412 (ISSN-L)
OpenAlex
W2549063601
Cited by
13
References
15
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2021: 4 · 2019: 2 · 2018: 1 · 2017: 1
FWCI
1.08
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Journal of Genetic Syndromes & Gene Therapy (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • HAL (submittedVersion, other-oa)
Funders
  • National Institute for Health and Care Research (NF-SI-0515-10047)
  • Medical Research Council (MR/K007629/1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
Keywords
ABCA4, gene therapy vectors, transgene expression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review